98 related articles for article (PubMed ID: 20846263)
21. Genetic and epigenetic changes of NKIRAS1 gene in human renal cell carcinomas.
Gerashchenko GV; Bogatyrova OO; Rudenko EE; Kondratov AG; Gordiyuk VV; Zgonnyk YM; Vozianov OF; Pavlova TV; Zabarovsky ER; Rynditch AV; Kashuba VI
Exp Oncol; 2010 Jul; 32(2):71-5. PubMed ID: 20693965
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients.
Bagadi SA; Prasad CP; Kaur J; Srivastava A; Prashad R; Gupta SD; Ralhan R
Life Sci; 2008 Jun; 82(25-26):1288-92. PubMed ID: 18538349
[TBL] [Abstract][Full Text] [Related]
23. Na,K-adenosine triphosphatase alpha1-subunit predicts survival of renal clear cell carcinoma.
Seligson DB; Rajasekaran SA; Yu H; Liu X; Eeva M; Tze S; Ball W; Horvath S; deKernion JB; Rajasekaran AK
J Urol; 2008 Jan; 179(1):338-45. PubMed ID: 18006011
[TBL] [Abstract][Full Text] [Related]
24. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.
Peters I; Rehmet K; Wilke N; Kuczyk MA; Hennenlotter J; Eilers T; Machtens S; Jonas U; Serth J
Mol Cancer; 2007 Jul; 6():49. PubMed ID: 17634119
[TBL] [Abstract][Full Text] [Related]
25. mRNA expression profiles of methylated APAF-1 and DAPK-1 tumor suppressor genes uncover clear cell renal cell carcinomas with aggressive phenotype.
Christoph F; Hinz S; Kempkensteffen C; Schostak M; Schrader M; Miller K
J Urol; 2007 Dec; 178(6):2655-9. PubMed ID: 17945286
[TBL] [Abstract][Full Text] [Related]
26. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
[TBL] [Abstract][Full Text] [Related]
27. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis.
Gonzalgo ML; Yegnasubramanian S; Yan G; Rogers CG; Nicol TL; Nelson WG; Pavlovich CP
Clin Cancer Res; 2004 Nov; 10(21):7276-83. PubMed ID: 15534102
[TBL] [Abstract][Full Text] [Related]
28. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
Minervini A; Di Cristofano C; Gacci M; Serni S; Menicagli M; Lanciotti M; Salinitri G; Rocca CD; Lapini A; Nesi G; Bevilacqua G; Minervini R; Carini M
J Urol; 2008 Oct; 180(4):1284-9. PubMed ID: 18707725
[TBL] [Abstract][Full Text] [Related]
29. Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma.
Lu B; Ma Y; Wu G; Tong X; Guo H; Liang A; Cong W; Liu C; Wang H; Wu M; Zhao J; Guo Y
Clin Cancer Res; 2008 Nov; 14(22):7405-12. PubMed ID: 19010857
[TBL] [Abstract][Full Text] [Related]
30. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
[TBL] [Abstract][Full Text] [Related]
31. Inactivation of p16 by CpG hypermethylation in renal cell carcinoma.
Vidaurreta M; Maestro ML; Sanz-Casla MT; Maestro C; Rafael S; Veganzones S; Moreno J; Blanco J; Silmi A; Arroyo M
Urol Oncol; 2008; 26(3):239-45. PubMed ID: 18452812
[TBL] [Abstract][Full Text] [Related]
32. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis.
Strathdee G; Holyoake TL; Sim A; Parker A; Oscier DG; Melo JV; Meyer S; Eden T; Dickinson AM; Mountford JC; Jorgensen HG; Soutar R; Brown R
Clin Cancer Res; 2007 Sep; 13(17):5048-55. PubMed ID: 17785556
[TBL] [Abstract][Full Text] [Related]
33. Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome.
Arai E; Ushijima S; Tsuda H; Fujimoto H; Hosoda F; Shibata T; Kondo T; Imoto I; Inazawa J; Hirohashi S; Kanai Y
Clin Cancer Res; 2008 Sep; 14(17):5531-9. PubMed ID: 18765545
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor mutations are associated with altered epigenomic programming as evidenced by HOXA5 methylation.
Bens S; Ammerpohl O; Martin-Subero JI; Appari M; Richter J; Hiort O; Werner R; Riepe FG; Siebert R; Holterhus PM
Sex Dev; 2011; 5(2):70-6. PubMed ID: 21311178
[TBL] [Abstract][Full Text] [Related]
35. [Correlation of aberrant methylation of MGMT gene to MTHFR C677T genetic polymorphisms in esophageal squamous cell carcinoma].
Xue HC; Wang JM; Xu B; Guo GP; Hua ZL; Zhou Q; Zhu ZH; Ma ZK; Gao J
Ai Zheng; 2008 Dec; 27(12):1256-62. PubMed ID: 19079989
[TBL] [Abstract][Full Text] [Related]
36. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
37. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
38. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
[TBL] [Abstract][Full Text] [Related]
39. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma.
Hou P; Ji M; Yang B; Chen Z; Qiu J; Shi X; Lu Z
Cancer; 2006 Apr; 106(7):1602-9. PubMed ID: 16502411
[TBL] [Abstract][Full Text] [Related]
40. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility.
Rodins K; Cheale M; Coleman N; Fox SB
Clin Cancer Res; 2002 Apr; 8(4):1075-81. PubMed ID: 11948116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
